Galera Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Galera Therapeutics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

Geri Alım Getirisi

Toplam Hissedar Getirisi	0%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Analiz Makalesi • Feb 15

Galera down ~8% after phase 1 data for non-small cell lung cancer combination treatment

Galera Therapeutics (NASDAQ:GRTX) stock has lost 7.8% to $1.42 in Wednesday morning trade after announcing phase 1 data for its molecule rucosopasem in combination with stereotactic body radiation therapy to treat patients with non-small cell lung cancer. The results from the early-stage phase of the GRECO-1 trial showed that rucosopasem was safe and well tolerated in a group of seven patients, GRTX said. The results also showed early indications of anti-cancer activity and pulmonary function preservation. GRTX said enrollment is now ongoing in the placebo-controlled phase 2 stage of the trial.

Analiz Makalesi • Jun 15

Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Seeking Alpha • Mar 23

Is Galera Therapeutics Stock A Buy, Sell, Or Hold? Several Catalysts To Watch In 2022

Galera Therapeutics is developing drugs that reduce side effects from anti-cancer radiotherapy and improve the treatment outcome. Clinical trial data have demonstrated statistically significant efficacy for the Avasopasem drug against severe oral mucositis. A pending meeting with the FDA this year could open the door for a new drug application. The stock looks interesting on the selloff.

Analiz Makalesi • Feb 24

Here's Why We're A Bit Worried About Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Seeking Alpha • Dec 24

Galera Therapeutics: Trial Reversal Did Not Take The Stock Higher

In October, GRTX announced that its phase 3 trial failed. In December, GRTX said the trial had actually succeeded. The stock tanked in October, then recovered in December, but not by as much.

Analiz Makalesi • Nov 04

Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analiz Makalesi • Aug 05

Will Galera Therapeutics (NASDAQ:GRTX) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analiz Makalesi • Feb 17

Here's Why We're Watching Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: GRTX.D şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: GRTX.D şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Galera Therapeutics Piyasaya Karşı Temettü Getirisi

GRTX.D temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (GRTX.D)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (GRTX.D) (3 yıla kadar)	n/a

Önemli Temettü: GRTX.D şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, GRTX.D şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: GRTX.D şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: GRTX.D herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Güçlü temettü ödeyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/07/14 21:27
Gün Sonu Hisse Fiyatı	2026/07/14 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Galera Therapeutics, Inc. 5 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Tazeen Ahmad	BofA Global Research
null null	BTIG
Yigal Nochomovitz	Citigroup Inc

Galera Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Obsidian Therapeutics, Inc. agreed to acquire Galera Therapeutics, Inc. (OTCPK:GRTX) in a reverse merger transaction.

Galera Therapeutics, Inc., Annual General Meeting, May 08, 2026

Galera Therapeutics Announces Board Changes

Galera Therapeutics, Inc., Annual General Meeting, Feb 24, 2025

Galera Therapeutics, Inc. announced delayed 10-Q filing

The Nasdaq Stock Market LLC to Delist Common Stock of Galera Therapeutics

Galera Therapeutics, Inc. Eliminates Robert A. Beardsley as Chief Operating Officer

Galera Therapeutics, Inc.(OTCPK:GRTX) dropped from S&P TMI Index

Nasdaq Hearings Panel Determines to Delist Galera Therapeutics' Shares from Nasdaq Due to the Failure to Meet Nasdaq’s Continued Listing Standards

New major risk - Financial position

Galera Therapeutics Receives Non-Compliance Letters from the Listing Qualifications Staff of Nasdaq

New major risk - Market cap size

New major risk - Revenue and earnings growth

Price target increased by 25% to US$0.50

Insufficient new directors

Galera Therapeutics Receives Notice from Nasdaq Regarding Listing Rule 5450(B)(2)(C)

Galera Therapeutics Receives Two Non-Compliance Notices from Nasdaq

New minor risk - Share price stability

Galera Therapeutics, Inc. Approves Reduction in the Company's Current Workforce by 22 Employees, or Approximately 70% of the Company's Headcount

Consensus revenue estimates increase by 17%

New minor risk - Market cap size

Galera Therapeutics, Inc. Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting

Insufficient new directors

Consensus revenue estimates increase by 100%

Price target decreased by 11% to US$10.00

CEO, President & Director recently bought US$168k worth of stock

Price target increased by 11% to US$12.50

Galera Therapeutics, Inc. Announces FDA Acceptance and Priority Review of Avasopasem NDA for Radiotherapy-Induced Severe Oral Mucositis

Galera Therapeutics (NASDAQ:GRTX) Will Have To Spend Its Cash Wisely

Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis

Galera Therapeutics Receives Non-Compliance Notice from Nasdaq

Price target decreased to US$11.25

Price target increased to US$15.00

Price target increased to US$15.00

Galera Therapeutics, Inc. Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting

Galera Therapeutics (NASDAQ:GRTX) Will Have To Spend Its Cash Wisely

Galera Therapeutics, Inc Appoints Eugene P. Kennedy as Chief Medical Officer

Galera Therapeutics appoints chief medical officer

Price target increased to US$15.00

Galera Therapeutics, Inc. Announces Results from Phase 1 Stage of Greco-1 Trial of Rucosopasem with SBRT for Nsclc

Galera down ~8% after phase 1 data for non-small cell lung cancer combination treatment

Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky

Galera Therapeutics Receives Non-Compliance Letter from Nasdaq

Galera Therapeutics, Inc. Announces Oral Presentation At 2022 American Society of Clinical Oncology Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem

Galera Announces Plan to Submit Avasopasem NDA by Year End

Galera Therapeutics, Inc. Announces Topline Results from Phase 2A Aesop Trial of Avasopasem for Chemoradiotherapy-Induced Esophagitis

Galera to Present at 2022 American Society of Clinical Oncology Annual Meeting

Price target increased to US$12.25

Is Galera Therapeutics Stock A Buy, Sell, Or Hold? Several Catalysts To Watch In 2022

Here's Why We're A Bit Worried About Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation

Galera Therapeutics: Trial Reversal Did Not Take The Stock Higher

Independent Director recently bought US$55k worth of stock

Galera Therapeutics, Inc. Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem

Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky

Price target decreased to US$11.50

Chief Medical Officer exercised options and sold US$288k worth of stock

Will Galera Therapeutics (NASDAQ:GRTX) Spend Its Cash Wisely?

Galera Therapeutics, Inc.(NasdaqGM:GRTX) dropped from Russell 3000E Index

Independent Director recently bought US$91k worth of stock

Galera Therapeutics, Inc. Ceases Enrolling Subjects in its Phase 2 Pilot Trial of Avasopasem in Hospitalized Patients

Independent Director recently bought US$173k worth of stock

Consensus forecasts updated

Galera Therapeutics, Inc. Announces First Patient Dosed with GC4711 in Phase 2b GRECO-2 Trial in Patients with Pancreatic Cancer

Price target increased to US$20.75

CEO, President & Director exercised options to buy US$1.8m worth of stock.

Here's Why We're Watching Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation

New 90-day high: US$12.39

Chief Accounting Officer exercised options and sold US$179k worth of stock

New 90-day high: US$12.81

New 90-day high: US$9.81

Galera Therapeutics, Inc.(NasdaqGM:GRTX) dropped from Russell 3000 Value Index

Galera Therapeutics, Inc.(NasdaqGM:GRTX) dropped from Russell Microcap Value Index

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç